NCI, EPA Attempt to Resolve Differences Over Childhood Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

BETHESDA, Md--Officials of the National Cancer Institute (NCI) and the Environmental Protection Agency (EPA) are attempting to resolve their conflicting interpretations of data regarding cancer in children. The NCI has forcefully challenged the EPA’s contention that the United States is in the midst of an epidemic of childhood malignancies.

BETHESDA, Md--Officials of the National Cancer Institute (NCI) and the Environmental Protection Agency (EPA) are attempting to resolve their conflicting interpretations of data regarding cancer in children. The NCI has forcefully challenged the EPA’s contention that the United States is in the midst of an epidemic of childhood malignancies.

An EPA conference last September declared that cancer in US children has increased steadily over the last quarter century and that the situation demands a focused program to determine the cause of the increase and find means of prevention. This led to a reassessment by NCI epidemiologists of data from the Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

Martha Linet, MD, who led the NCI review, said that her group found "no evidence of a consistent increase in the incidence during 1973 to 1994 for specific types of childhood cancer."

In late January, senior EPA and NCI officials met for more than 2 hours to discuss the childhood cancer data, Hugh W. McKinnon, MD, of EPA’s National Risk Management Research Laboratory in Cincinnati, reported at the NCAB February meeting. They agreed that staff scientists from the two agencies would hold further meetings to try to resolve the conflicting interpretation of the childhood cancer statistics.

"Honest scientists will have honest disagreements over data, and we are trying to understand that data," Dr. McKinnon told Oncology News International.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content